SeaStar Medical Holding Corporation (NASDAQ:ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces enrollment of the first
According to a U.K. trial, Eliquis (apixaban), widely prescribed for COVID-19, did not help patients recovering from moderate and severe COVID.
The drug used after discharge from the hospital does not lessen the chances for COVID-19 patients of readmission or improve survival.